![Frontiers | Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence Frontiers | Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence](https://www.frontiersin.org/files/Articles/1003103/fmed-09-1003103-HTML/image_m/fmed-09-1003103-g001.jpg)
Frontiers | Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence
![The compartmentalized upper respiratory mucosa needs time to rally a sufficient immune force for SARS-CoV-2 clearance | Cellular & Molecular Immunology The compartmentalized upper respiratory mucosa needs time to rally a sufficient immune force for SARS-CoV-2 clearance | Cellular & Molecular Immunology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41423-022-00931-9/MediaObjects/41423_2022_931_Fig1_HTML.png)
The compartmentalized upper respiratory mucosa needs time to rally a sufficient immune force for SARS-CoV-2 clearance | Cellular & Molecular Immunology
The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Un
![Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study - The Lancet Infectious Diseases Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/3a32455a-3dd0-4fd2-801f-4618d4f4c57a/gr1.jpg)